AbbVie Announces Global Resolution of HUMIRA®
AbbVie proclaimed that it has finalized a deal with Samsung Bioepis and their joint venture partner Biogen Inc. that would deter U.S. competition of their biosimilar version to blockbuster drug Humira (Adalimumab) until 2023. This would mark the second deal AbbVie has made in the past year, trying to protect patents on their favorable drug, Humira.
